Eric Palmer

Biography for Eric Palmer

Eric Palmer, Senior Editor

Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at epalmer@fiercemarkets.com.

Articles by Eric Palmer

Spinoff fervor grows: GSK looks at ViiV spinoff and investor tells Amgen to break things up

GlaxoSmithKline said today it is considering a spinoff of ViiV, the successful HIV-centric business it shares with Pfizer and Shionogi. Its talk of unlocking the "intrinsic" value of the business mirrored the language a hedge fund investor used hours earlier to suggest that Amgen do much the same thing, breaking into two companies, one for legacy drugs and one for new launches.

Bristol-Myers catches a break as Indian agency delays Sprycel patent decision

Prime Minister Narendra Modi got an ear full from both constituents and the U.S. drug industry about India's approach to drug patents during his first visit to the U.S. last month. Three weeks later, there is evidence the government will take a considered approach to the contested issue.

AbbVie's $1.635B breakup fee to Shire, if paid, will run third highest ever

Breaking up is hard to do, and can be expensive. AbbVie is getting into record territory with the $1.635 billion breakup fee it will have to pay Shire for canceling their $55 billion deal.

Lilly will close Puerto Rico plant, affecting 100 workers

It has been a tale of two cities when it comes to Eli Lilly's operations in Puerto Rico. Its plant in Carolina has been slotted for $240 million in investments in the last year, benefiting from its buildup in insulin products, and its plant in Guayama is getting axed, a victim of patent losses.

Hospira says saline recall will not make shortage worse

Hospira, the country's largest producer of sterile drugs, is recalling two dozen lots of saline solution, along with 30 lots of other products, because the bags on one of its delivery systems can leak and products might get contaminated.

AbbVie-Shire deal in jeopardy, but not necessarily dead

Shire, which believed only a day ago that it would soon be bought out by AbbVie in a $54 billion deal prompted by tax advantages, is not going to just roll over and play dead now that its pursuer is getting cold feet. It insists the deal should go through.

Novartis' Russian growth plans get delayed

Novartis is reportedly caught between EU sanctions on Russia and the dictates of Russian President Vladimir Putin, who has told Western drugmakers that he expects them to build plants and transfer technology as the price of admission to the growing market.

India's NPPA fines Novartis $49M as price cap battles rage on

India's National Pharmaceutical Pricing Authority has fined Novartis the equivalent of $49 million for overpricing its popular pain drug Voveran, and Novartis has responded by challenging NPPA's authority to do so. The fine is just the latest move in an escalating battle between drugmakers and the NPPA.

GSK corruption allegations now surface in UAE

A day after Sanofi informed U.S. officials it was looking into reports of employees paying bribes in the Middle East, GlaxosmithKline said it was doing the same in the United Arab Emirates.

Sovaldi's nosebleed price reflects a trend, not an exception to the rule

Gilead Sciences' $84,000-per-treatment-course hep C drug Sovaldi reached blockbuster status twice over in the course of a single quarter. But instead of an aberration, a new report suggests it is a reflection of a trend that has been going on for 5 years and looks to be the new normal.